A new clinical study indicates that cannabis-derived medicinal extracts may help reduce several symptoms associated with cancer, including difficulty sleeping and anxiety, though patient responses varied considerably depending on which cannabinoid profile worked best for each individual.
The study team evaluated oil-based formulations with different proportions of cannabidiol (CBD) and tetrahydrocannabinol (THC) using a randomized, placebo-controlled trial that was triple-blinded to reduce bias.
Overall results suggest that cannabis oil treatments produced meaningful relief in about half of participants, with improvements most often reported in sleep-related issues and closely connected symptoms. When outcomes were averaged across the study population, no single formulation consistently showed superior performance compared with the others.
Among the 89 participants who had complete Patient Global Impression of Change records, 56% experienced at least a 1.4-point improvement relative to placebo when using one or more active extracts. In subgroup analyses, response rates were recorded at 50% for pain, 47% for sleep difficulties, and 60% for anxiety. Around two-thirds of participants said they preferred an active cannabinoid product over placebo.
The study also found that a low-dose regimen combining 2.5 milligrams of THC and CBD taken three times per day was generally well tolerated. Even so, the researchers stressed that better outcomes are likely achieved when treatment is tailored rather than standardized across patients.
According to the authors, a universal recommendation is unlikely to fit the wide range of biological differences seen in patients. Variations in the endocannabinoid system may help explain why some individuals respond better to certain extracts than others.
The findings add to expanding scientific work exploring cannabis compounds in cancer care. Earlier reviews have suggested possible anti-tumor activity in specific cancers such as glioblastoma and breast tumors, along with evidence that cannabinoids may improve the effectiveness of chemotherapy.
CBD has also been highlighted in multiple analyses for its potential anti-cancer properties, anti-inflammatory effects, and possible role in slowing tumor growth and spread across cancers including lung, colorectal, ovarian, and prostate.
A 2025 study also examined existing clinical and laboratory data, suggesting cannabinoid use may enhance how standard chemotherapy drugs perform.
Separately, earlier research has reported that many cancer patients who use cannabis describe noticeable improvements in symptom severity and overall quality of life.
Researchers say further large-scale trials will be needed to determine optimal dosing strategies and long-term safety, particularly as interest in cannabinoid-based therapies continues to grow in oncology care settings worldwide.
These scientific findings confirming that marijuana products indeed confer medical benefits upon cancer patients are likely to be welcomed by industry firms like Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) that sell medical marijuana products aimed at helping cancer patients manage their symptoms.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
